A Phase 3, multicenter, double-blind, randomized, placebocontrolled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (CHONQUER study.

Datos básicos

ENSAYO CLÍNICO CL3-95031-007 HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE Año de incio: 2025

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

LABORATORIOS SERVIER SL

Cita

Compartir